Roles of BCL6 in normal and transformed germinal center B cells

Immunological Reviews

Volumn 247, Issue 1, 2012, Pages 172-183

  Basso, Katia ^a   Dalla Favera, Riccardo ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

B cell differentiation; BCL6; DNA damage response; Germinal center; Non Hodgkin B cell lymphoma; TP53

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 6; PROTEIN P53; RNA; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; ZINC FINGER PROTEIN;

ACETYLATION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CHROMOSOME TRANSLOCATION; DNA BINDING; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC CODE; GENETIC DISORDER; GERM CELL; GERMINAL CENTER; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOMATIC HYPERMUTATION; T LYMPHOCYTE; TRANSCRIPTION REGULATION; ZINC FINGER MOTIF;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; GERMINAL CENTER; HUMANS; LYMPHOMA, NON-HODGKIN; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSCRIPTIONAL ACTIVATION;

EID: 84859715609     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01112.x     Document Type: Article

References (83)

1. Ye BH, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993;262:747-750.
2. Wong CW, Privalsky ML. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. J Biol Chem 1998;273:27695-27702.
3. Lemercier C, et al. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 2002;277:22045-22052.
4. Huynh KD, Bardwell VJ. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 1998;17:2473-2484.
5. Dhordain P, et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci USA 1997;94:10762-10767.
6. Huynh KD, et al. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev 2000;14:1810-1823.
7. Ahmad KF, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell 2003;12:1551-1564.
8. Mendez LM, et al. CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol 2008;28:2175-2186.
9. Fujita N, et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 2004;119:75-86.
10. Parekh S, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007;110:2067-2074.
11. Basso K, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood 2010;115:975-984.
12. Phan RT, et al. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005;6:1054-1060.
13. Saito M, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2009;106:11294-11299.
14. Chang CC, et al. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA 1996;93:6947-6952.
15. Kawamata N, et al. Recognition DNA sequence of a novel putative transcription factor, BCL6. Biochem Biophys Res Commun 1994;204:366-374.
16. Ci W, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 2009;113:5536-5548.
17. Johnston RJ, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009;325:1006-1010.
18. Nurieva RI, et al. Bcl6 mediates the development of T follicular helper cells. Science 2009;325:1001-1005.
19. Yu D, et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 2009;31:457-468.
20. Klein U, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 2003;100:2639-2644.
21. Kerfoot SM, et al. Germinal center B cell and T follicular helper cell development initiates in the interfollicular zone. Immunity 2011;34:947-960.
22. Kitano M, et al. Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. Immunity 2011;34:961-972.
23. Lee CH, et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med 2006;203:63-72.
24. Pasqualucci L, et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003;101:2914-2923.
25. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002;32:606-613.
26. Phan RT, et al. Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells. Nat Immunol 2007;8:1132-1139.
27. Niu H, Ye BH, Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 1998;12:1953-1961.
28. Allman D, et al. BCL-6 expression during B-cell activation. Blood 1996;87:5257-5268.
29. Basso K, et al. Tracking CD40 signaling during germinal center development. Blood 2004;104:4088-4096.
30. Niu H, Cattoretti G, Dalla-Favera R. BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells. J Exp Med 2003;198:211-221.
31. Saito M, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007;12:280-292.
32. Duan S, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 2012;481:90-93.
33. Shaffer AL, et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
34. Polo JM, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004;10:1329-1335.
35. Tunyaplin C, et al. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004;173:1158-1165.
36. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004;432:635-639.
37. Polo JM, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2007;104:3207-3212.
38. Basso K. Toward a systems biology approach to investigate cellular networks in normal and malignant B cells. Leukemia 2009;23:1219-1225.
39. Borriello F, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 1997;6:303-313.
40. Keir ME, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
41. Shapiro-Shelef M, et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003;19:607-620.
42. Angelin-Duclos C, et al. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol 2000;165:5462-5471.
43. Falini B, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084-2092.
44. Klein U, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006;7:773-782.
45. Sciammas R, et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006;25:225-236.
46. Cattoretti G, et al. Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol 2006;177:6930-6939.
47. Basso K, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal-center B cells. Blood 2010;115:975-984.
48. Ding BB, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;111:1515-1523.
49. Fornek JL, et al. Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood 2006;107:1085-1091.
50. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005;438:364-368.
51. Meyer-Bahlburg A, Khim S, Rawlings DJ. B cell intrinsic TLR signals amplify but are not required for humoral immunity. J Exp Med 2007;204:3095-3101.
52. Cazac BB, Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000;13:443-451.
53. Yu Q, et al. Role of beta-catenin in B cell development and function. J Immunol 2008;181:3777-3783.
54. Ranuncolo SM, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007;8:705-714.
55. Ranuncolo SM, Polo JM, Melnick A. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells Mol Dis 2008;41:95-99.
56. Zacchi P, et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002;419:853-857.
57. Zheng H, et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002;419:849-853.
58. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606.
59. Brooks CL, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011;2:456-462.
60. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609-622.
61. Ye BH, et al. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res 1993;53:2732-2735.
62. Baron BW, et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc Natl Acad Sci USA 1993;90:5262-5266.
63. Kerckaert JP, et al. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet 1993;5:66-70.
64. Lo Coco F, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994;83:1757-1759.
65. Butler MP, et al. Alternative translocation breakpoint cluster region 5′ to BCL-6 in B-cell non-Hodgkin's lymphoma. Cancer Res 2002;62:4089-4094.
66. Ye BH, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 1995;14:6209-6217.
67. Chen W, et al. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. Blood 1998;91:603-607.
68. Shen HM, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998;280:1750-1752.
69. Pasqualucci L, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci USA 1998;95:11816-11821.
70. Wang X, et al. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2002;99:15018-15023.
71. Miller RW, Rubinstein JH. Tumors in Rubinstein-Taybi syndrome. Am J Med Genet 1995;56:112-115.
72. Petrij F, et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995;376:348-351.
73. Pasqualucci L, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189-195.
74. Cattoretti G, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005;7:445-455.
75. Pasqualucci L, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008;40:108-112.
76. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
77. Iqbal J, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007;21:2332-2343.
78. Monti S, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-1861.
79. Cerchietti LC, et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009;113:3397-3405.
80. Cerchietti LC, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010;17:400-411.
81. Cerchietti LC, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 2009;15:1369-1376.
82. Kirschbaum M, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:1198-1203.
83. Cerchietti LC, et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest 2010;120:4569-4582.